Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.

The Journal of antimicrobial chemotherapy - 1 Oct 2016

Hayashida Tsunefusa, Hachiya Atsuko, Ode Hirotaka, Nishijima Takeshi, Tsuchiya Kiyoto, Sugiura Wataru, Takiguchi Masafumi, Oka Shinichi, Gatanaga Hiroyuki

Abstract excerpt

BACKGROUND: Rilpivirine is listed as a recommended or alternative key drug in the current ART guidelines. E138K in HIV-1 reverse transcriptase (RT) is a primary mutation in resistance to rilpivirine, although in vitro experiments showed it confers only <3-fold resistance. An unidentified mechanism could amplify resistance to rilpivirine conferred by E138K. OBJECTIVES: The objective of this study was to reveal the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Reverse Transcriptase

Share to Rilpivirine

Share to Treatment Failure

Share to Virus Replication

Source

Identifiers

PMID: 27330069
DOI: 10.1093/jac/dkw224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.PMID 27330069Read ↗

Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey.Semantic proximity Read ↗

Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.Semantic proximity Read ↗

Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.Semantic proximity Read ↗

Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults.Semantic proximity Read ↗

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.Semantic proximity Read ↗

Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Semantic proximity Read ↗

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.Semantic proximity Read ↗

The efficacy of first-line ART regimens based on RPV in HIV-infected patients with pre-existing E138A mutation in reverse transcriptaseSemantic proximity Read ↗

[Resistance profile of rilpivirine].Semantic proximity Read ↗

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settingsSemantic proximity Read ↗

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.Semantic proximity Read ↗

Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.